Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule

References

• World Health Organization. Comprehensive cervical cancer control: A guide to essential practice. 2nd ed. Geneva: World Health Organization Press; 2014.
   Google Scholar
• Iversen O-E, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. Jama. 2016;316(22):2411–6. doi:10.1001/jama.2016.17615.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2016;12(1):20–29. doi:10.1080/21645515.2015.1065363.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Executive board, session 144; document EB144/28. 2019 Jan 30.
   Google Scholar
• World Health Organization. Global market study: HPV. 2019.
   Google Scholar
• Brotherton JM, Budd A, Rompotis C, Bartlett N, Malloy MJ, Andersen RL, Coulter KA, Couvee PW, Steel N, Ward GH, et al. Is one dose of human papillomavirus vaccine as effective as three?: a national cohort analysis. Papillomavirus Res (Amsterdam, Netherlands). 2019;8:100177. doi:10.1016/j.pvr.2019.100177.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, Schiffman M, Rodriguez AC, Chanock S, Jimenez S, et al. Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36(32):4774–82. doi:10.1016/j.vaccine.2017.12.078.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2020;8(2):e191–e203. doi:10.1093/jnci/djr319.
   Google Scholar
• Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36(32):4761–67. doi:10.1016/j.vaccine.2018.02.003.
   PubMed Web of Science ®Google Scholar
• LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress in HPV vaccination in low- and lower-middle-income countries. Int J Gynaecol Obstet. 2017;138(Suppl 1):7–14. doi:10.1002/ijgo.12186.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Working group on potential contribution of Human Papillomavirus (HPV) vaccines and immunization towards cervical cancer elimination: background document and report to SAGE. 2019.
   Google Scholar
• Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F.Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203. doi:10.1016/S2214-109X(19)30482-6.
   PubMed Web of Science ®Google Scholar
• Ginsburg OM. Breast and cervical cancer control in low and middle-income countries: human rights meet sound health policy. J Cancer Policy. 2013;1(3–4):e34–e41. doi:10.1016/j.jcpo.2013.07.002.
   Google Scholar
• Stanley M, Dull P. HPV single-dose vaccination: impact potential, evidence base and further evaluation. Vaccine. 2018;36(32Pt A):4759–60. doi:10.1016/j.vaccine.2018.02.076.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position on HPV vaccines. Vaccine. 2009;27(52):7236–37. doi:10.1016/j.vaccine.2009.05.019.
   PubMedGoogle Scholar
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5(5)):F123–138. doi:10.1016/j.vaccine.2012.04.108.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli URR, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36(32):4783–91. doi:10.1016/j.vaccine.2018.02.087.
   PubMed Web of Science ®Google Scholar
• Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, De Melker HE. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis. J Infect. 2015;71(1):61–73. doi:10.1016/j.jinf.2015.02.005.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization Technical Advisory Group. Technical Advisory Group on vaccine-preventable diseases (TAG). 2014.
   Google Scholar
• European Medicines Agency. Annex 1: summary of product characteristics. 2015.
   Google Scholar
• Scientific evaluation of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines. [accessed 2020 August 10]. https://ClinicalTrials.gov/show/NCT03180034
   Google Scholar
• Markowitz LE, Drolet M, Perez N, Jit M, Brisson M. Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs. Vaccine. 2018;36(32):4806–15. doi:10.1016/j.vaccine.2018.01.057.
   PubMed Web of Science ®Google Scholar
• Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR, Basu P, Kelly H, Drolet M, Brisson M, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine. 2020;38(6):1302–14. doi:10.1016/j.vaccine.2019.12.017.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National health and nutrition examination surveys, 2003–2010. J Infect Dis. 2013;208(3):385–93. doi:10.1093/infdis/jit192.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli URR, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67–77. doi:10.1016/S1470-2045(15)00414-3.
   PubMed Web of Science ®Google Scholar
• Tsang SH, Sampson JN, Schussler J, Porras C, Wagner S, Boland J, Cortes B, Lowy DR, Schiller JT, Schiffman M, et al. Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020;112(10):1030–37. doi:10.1093/jnci/djaa010.
   PubMedGoogle Scholar
• Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32):4768–73. doi:10.1016/j.vaccine.2017.12.079.
   PubMed Web of Science ®Google Scholar
• Kumar S, Biswas M, Jose T. HPV vaccine: current status and future directions. Med J Armed Forces India. 2015;71(2):171–77. doi:10.1016/j.mjafi.2015.02.006.
   PubMedGoogle Scholar
• Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, Wang F, Wang N, Wang B, Wang Y, et al. Evaluation of the Thermal Stability of Gardasil®. Hum Vaccin. 2006;2(4):147–54. doi:10.4161/hv.2.4.2989.
   PubMed Web of Science ®Google Scholar
• Burger EA, Campos NG, Sy S, Regan C, Kim JJ. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine. 2018;36(32):4823–29. doi:10.1016/j.vaccine.2018.04.061.
   PubMed Web of Science ®Google Scholar
• Gallagher KE, Kelly H, Cocks N, Dixon S, Mounier-Jack S, Howard N, Watson-Jones D. Vaccine programme stakeholder perspectives on a hypothetical single-dose human papillomavirus (HPV) vaccine schedule in low and middle-income countries. Papillomavirus Res (Amsterdam, Netherlands). 2018;6:33–40. doi:10.1016/j.pvr.2018.10.004.
   PubMed Web of Science ®Google Scholar
• Upshur RE. Seven characteristics of medical evidence. Journal of Evaluation in Clinical Practice. 2000;6(2):93–97. doi:10.1046/j.1365-2753.2000.00244.x.
   PubMed Web of Science ®Google Scholar
• Weijer C. The future of research into rotavirus vaccine. BMJ (Clinical Research Ed). 2000;321(7260):525–26. doi:10.1136/bmj.321.7260.525.
   PubMed Web of Science ®Google Scholar
• Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317(3):141–45. doi:10.1056/NEJM198707163170304.
   PubMed Web of Science ®Google Scholar
• Rawls J. A theory of justice. Cambridge (MA): The Belknap Press of Havard University Press; 1971.
   Google Scholar
• Gallagher KE, Howard N, Kabakama S, Mounier-Jack S, Griffiths UK, Feletto M, Burchett HED, LaMontagne DS, Watson-Jones D. Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries. PloS One. 2017;12(6):e0177773. doi:10.1371/journal.pone.0177773.
   PubMed Web of Science ®Google Scholar
• The Vaccine GAVI Alliance. Millions of girls in developing countries to be protected against cervical cancer thanks to new HPV vaccine deals. 2013 [accessed 2020 Jun 9]. https://www.gavi.org/hpv-price-announcement.
   Google Scholar
• Upshur REG We need both evidence and values to navigate uncertainty. Hastings Center Report. 2014 Sept–Oct 4.
   Google Scholar